See more : Capitala Finance Corp. (CPTAL) Income Statement Analysis – Financial Results
Complete financial analysis of Diagonal Bio AB (publ) (DIABIO.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Diagonal Bio AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Companhia Melhoramentos de São Paulo (MSPA4.SA) Income Statement Analysis – Financial Results
- Life Time Group Holdings, Inc. (LTH) Income Statement Analysis – Financial Results
- Airport City Ltd. (ARPT.TA) Income Statement Analysis – Financial Results
- Ocado Group plc (OCDGF) Income Statement Analysis – Financial Results
- Credit Suisse Group AG (CS) Income Statement Analysis – Financial Results
Diagonal Bio AB (publ) (DIABIO.ST)
About Diagonal Bio AB (publ)
Diagonal Bio AB operates as a biotechnology company in Sweden. It is involved in developing the Panviral platform for detecting and diagnosing small sections of pathogen genomes, such as viruses, bacteria, and fungi. The company was founded in 2020 and is headquartered in Lund, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 23.00K | 203.00K | 407.00K | 20.31K |
| Cost of Revenue | -3.11M | -1.85M | 492.00K | 627.86K |
| Gross Profit | 3.13M | 2.05M | -85.00K | -607.55K |
| Gross Profit Ratio | 13,621.74% | 1,011.82% | -20.88% | -2,991.39% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 7.10M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.68M | 17.22M | 7.10M | 740.00K |
| Other Expenses | 22.00K | 17.22M | 4.48M | 0.00 |
| Operating Expenses | 14.70M | 17.22M | 11.58M | 708.00K |
| Cost & Expenses | 11.57M | 15.37M | 12.07M | 627.86K |
| Interest Income | 94.00K | 1.00M | 0.00 | 0.00 |
| Interest Expense | 206.00K | 1.00M | 0.00 | 0.00 |
| Depreciation & Amortization | 3.00K | 15.16M | 11.66M | 777.33K |
| EBITDA | -11.47M | 0.00 | -11.66M | 193.97K |
| EBITDA Ratio | -49,865.22% | -7,469.46% | -2,865.60% | 835.96% |
| Operating Income | -11.57M | -15.16M | -11.66M | -607.55K |
| Operating Income Ratio | -50,286.96% | -7,469.46% | -2,865.60% | -2,991.38% |
| Total Other Income/Expenses | -112.00K | -1.00M | 0.00 | 24.19K |
| Income Before Tax | -11.68M | -16.16M | -11.66M | -583.36K |
| Income Before Tax Ratio | -50,773.91% | -7,962.56% | -2,865.60% | -2,872.28% |
| Income Tax Expense | 0.00 | -15.16M | -11.69M | 0.00 |
| Net Income | -11.68M | -16.16M | -11.66M | -583.36K |
| Net Income Ratio | -50,773.91% | -7,962.56% | -2,865.60% | -2,872.28% |
| EPS | -0.32 | -1.70 | -1.70 | -0.17 |
| EPS Diluted | -0.32 | -1.70 | -1.70 | -0.17 |
| Weighted Avg Shares Out | 36.48M | 9.50M | 6.88M | 3.50M |
| Weighted Avg Shares Out (Dil) | 36.48M | 9.50M | 6.88M | 3.50M |
No news found for: DIABIO.ST
Source: https://incomestatements.info
Category: Stock Reports